Sartans: What they are for, how they degrade, where they are found and how they transform

Adams, 2000, Irbesartan: review of pharmacology and comparative properties, Can. J. Clin. Pharmacol., 7, 22 2005 2010 2018 Bauer, 1998, NMR Study of desmotropy in Irbesartan, a tetrazole-containing pharmaceutical compound, J. Chem. Soc., Perkin Trans., 2, 475, 10.1039/a708038g Bayer, 2014, Behavior of sartans antihypertensive drugs in wastewater treatment plants, their occurrence and risk for the aquatic environment, Environ. Sci. Pollut. Res., 21, 10830, 10.1007/s11356-014-3060-z Bergmann, 2011, vol. 6 Berkner, 2014, Biodegradability and transformation of human pharmaceutical active ingredients in environmentally relevant test systems, Environ. Sci. Pollut. Res., 21, 9461, 10.1007/s11356-013-1868-6 Bhardwaj, 2006, How the antihypertensive Losartan was discovered, Expet Opin. Drug Discov., 1, 609, 10.1517/17460441.1.6.609 Bianchini, 2011, Characterization of two new potential impurities of Valsartan obtained under photodegradation stress condition, J. Pharmaceut. Biomed. Anal., 56, 16, 10.1016/j.jpba.2011.04.017 Bodapati, 2015, Stability indicating RP-HPLC studies for the estimation of Irbesartan and amlodipine besilate in pharmaceutical formulations and identification and characterization of degradants using LC-MS, J. Liq. Chromatogr. Relat. Technol., 38, 259, 10.1080/10826076.2014.903851 Caussade, 1995, In vitro pharmacological characterization of UP 269-6, a novel nonpeptide angiotensin II receptor antagonist, Fund. Clin. Pharmacol., 9, 119, 10.1111/j.1472-8206.1995.tb00271.x Cockcroft, 1995, The effect of HN-65021 on responses to angiotensin II in human forearm vasculature, Bri. J. Clin. ical Pharmacol., 40, 591, 10.1111/j.1365-2125.1995.tb05804.x Destro, 2011, Telmisartan: just an antihypertensive agent? A literature review, Expet Opin. Drug Discov., 12, 2719 Dina, 2000, Angiotensin II-receptor antagonists: an overview, Am. J. Health Syst. Pharm., 57, 1231, 10.1093/ajhp/57.13.1231 2003, Stability testing of new drug substances and products 1998, Stability testing: photostability testing of new drug substances and products 2006, Impurities in new drug substances, Step 4 2006, Impurities in new drug product, Step 4 Fent, 2006, Ecotoxicology of human pharmaceuticals, Aquat. Toxicol., 76, 122, 10.1016/j.aquatox.2005.09.009 Gracia-Lor, 2012, Multi-class determination of personal care products and pharmaceuticals in environmental and wastewater samples by ultra-high performance liquid-chromatography-tandem mass spectrometry, Talanta, 99, 1011, 10.1016/j.talanta.2012.07.091 Helbling, 2010, High-throughput identification of microbial transformation products of organic micropollutants, Environ. Sci. Technol., 44, 6621, 10.1021/es100970m Huerta-Fontela, 2011, Occurrence and removal of pharmaceuticals and hormones through drinking water treatment, Water Res., 45, 1432, 10.1016/j.watres.2010.10.036 Iouzalen, 1999, Effects of BAY 10-6734 (Embusartan), a new angiotensin II type I receptor antagonist, on vascular smooth muscle cell growth, J. Pharmacol. Exp. Therapeut., 289, 181 Israili, 2000, Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension, J. Hum. Hypertens., 14, S73, 10.1038/sj.jhh.1000991 Fick, 2011 Jani, 2012, Dual action molecules: bioassays of combined novel antioxidants and angiotensin II receptor antagonists, Eur. J. Pharmacol., 695, 96, 10.1016/j.ejphar.2012.08.003 Judd, 1994, Bromobenzofuran-based non-peptide antagonists of angiotensin II: GR138950, a potent antihypertensive agent with high oral bioavailability, J. Med. Chem., 37, 3108, 10.1021/jm00045a016 Kårelid, 2017, Pilot-scale removal of pharmaceuticals in municipal wastewater: comparison of granular and powdered activated carbon treatment at three wastewater treatment plants, J. Environ. Manag., 193, 491, 10.1016/j.jenvman.2017.02.042 Kasprzyk-Hordern, 2008, The occurrence of pharmaceuticals, personal care products, endocrine disruptors and illicit drugs in surface water in South Wales, UK, Water Res., 42, 3498, 10.1016/j.watres.2008.04.026 Kasprzyk-Hordern, 2009, Illicit drugs and pharmaceuticals in the environment-forensic applications of environmental data, part 2: pharmaceuticals as chemical markers of faecal water contamination, Environ. Pollut., 157, 1778, 10.1016/j.envpol.2009.02.019 Kaushik, 2016, Forced degradation, LC–UV, MSn and LC–MS–TOF studies on Azilsartan: identification of a known and three new degradation impurities, J. Pharmaceut. Biomed. Anal., 120, 202, 10.1016/j.jpba.2015.12.027 Kern, 2010, A tiered procedure for assessing the formation of biotransformation products of pharmaceuticals and biocides during activated sludge treatment, J. Environ. Monit., 12, 2100, 10.1039/c0em00238k Klosterhaus, 2013, Method validation and reconnaissance of pharmaceuticals, personal care products, and alkilphenols in surface waters, sediments, and mussels in an urban estuary, Environ. Int., 54, 92, 10.1016/j.envint.2013.01.009 Knopf, 2013, Arzneimittelanwendung von Erwachsenen in deutschland, Bundesgesundheitsblatt - Gesundheitsforsch. - Gesundheitsschutz, 10.1007/s00103-013-1667-8 Kovalova, 2012, Hospital wastewater treatment by membrane bioreactor: performance and efficiency for organic micropollutant elimination, Environ. Sci. Technol., 46, 1536, 10.1021/es203495d Krovat, 2003, Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification, J. Med. Chem., 46, 716, 10.1021/jm021032v Margot, 2013, Treatment of micropollutants in municipal wastewater: ozone or powdered activated carbon?, Sci. Total Environ., 461–462, 480, 10.1016/j.scitotenv.2013.05.034 McClellan, 1998, Candesartan Cilexetil. Drugs, 56, 847, 10.2165/00003495-199856050-00013 Meredith, 2005, Angiotensin II Receptor antagonists alone and combined with hydrochlorothiazide, Am. J. Cardiovasc. Drugs, 5, 171, 10.2165/00129784-200505030-00004 Mire, 2005, A review of the structural and functional features of Olmesartan Medoxomil, an Angiotensin receptor blocker, J. Cardiovasc. Pharmacol., 46, 585, 10.1097/01.fjc.0000180902.78230.fd Murakami, 2008, Identification of a degradation product in stressed tablets of Olmesartan Medoxomil by the complementary use of HPLC hyphenated techniques, J. Pharmaceut. Biomed. Anal., 47, 553, 10.1016/j.jpba.2008.02.021 Mutha, 2018, Degradation study of Irbesartan: isolation and structural elucidation of novel degradants, J. Pharmaceut. Biomed. Anal., 157, 180, 10.1016/j.jpba.2018.05.009 Newswire Nödler, 2013, Occurrence and fate of the angiotensin II receptor antagonist transformation product Valsartan Acid in the water cycle–A comparative study with selected β-blockers and the persistent anthropogenic wastewater indicators carbamazepine and acesulfame, Water Res., 47, 6650, 10.1016/j.watres.2013.08.034 Petrie, 2015, A review on emerging contaminants in wastewaters and the environment: current knowledge, understudied areas and recommendations for future monitoring, Water Res., 72, 3, 10.1016/j.watres.2014.08.053 Pradhan, 2019, Fimasartan: a new armament to fight hypertension, J. Fam. Med. Prim. Care, 8, 2184, 10.4103/jfmpc.jfmpc_300_19 Rakibe, 2019, UPLC, HR-MS, and in-silico tools for simultaneous separation, characterization, and in-silico toxicity prediction of degradation products of Atorvastatin and Olmesartan, Acta Chromatogr., 31, 33, 10.1556/1326.2017.00333 Robins, 2005, Eprosartan. Drugs, 65, 2355, 10.2165/00003495-200565160-00012 Romanucci, 2020, Disinfection by-products and ecotoxic risk associated with hypochlorite treatment of irbesartan, Sci. Total Environ., 712, 135625, 10.1016/j.scitotenv.2019.135625 Schramm, 2012, Targeting NADPH oxidases in vascular pharmacology, Vasc. Pharmacol., 56, 216, 10.1016/j.vph.2012.02.012 Seburg, 2006, Photosensitized degradation of Losartan Potassium in an extemporaneous suspension formulation, J. Pharmaceut. Biomed. Anal., 42, 411, 10.1016/j.jpba.2006.04.030 Shah, 2010, Identification and characterization of degradation products of Irbesartan using LC–MS/TOF, MSn, on-line H/D exchange and LC–NMR, J. Pharmaceut. Biomed. Anal., 51, 1037, 10.1016/j.jpba.2009.11.008 Timmermans, 1995, Pharmacological properties of angiotensin II receptor antagonists, Can. J. Cardiol., 15 Timmermans, 1999, Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics, Hypertens. Res., 22, 147, 10.1291/hypres.22.147 Unceta, 2010, Multi-residue analysis of pharmaceutical compounds in wastewaters by dual solid-phase microextraction coupled to liquid chromatography electrospray ionization ion trap mass spectrometry, J. Chromatogr. A, 1217, 3392, 10.1016/j.chroma.2010.03.008 Vyas, 2010, Substituted benzimidazole derivatives as angiotensin II-AT1 receptor antagonist: a review, Mini Rev. Med. Chem., 10, 1366, 10.2174/138955710793564151 Weltman, 2012, Assessment of the environmental fate and effects of azilsartan, a selective antagonist of angiotensin II type 1, Chemosphere, 87, 1323, 10.1016/j.chemosphere.2012.01.053 Zaiken, 2011, Azilsartan Medoxomil: a new angiotensin receptor blocker, Clin. Therapeut., 33, 1577, 10.1016/j.clinthera.2011.10.007